Microsoft vs Sana Biotechnology Inc — how do they compare? Microsoft trades at $491.35 (market cap $3.74T), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Microsoft is far larger — about 3309.7× Sana Biotechnology Inc's market cap, and Microsoft pays a 0.72% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MSFT | SANA | |
|---|---|---|
Market Cap | $3.74T | $1.13B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $5.92 |
52-Week Low | $352.83 | $2.68 |
Enterprise Value | $3.72T | $1.05B |
Dividend Yield | 0.72% | — |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $493.21, down 2.54% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 estimate. Revenue grew to $281.72 billion in 2025, supported by a net income margin of 40.31% and robust cash flow from operations of $136.16 billion. Recent news highlights AI leadership and Azure momentum, though capital expenditure concerns persist.
Outlook remains positive with an 80.49% analyst buy rating and a $555 consensus price target, implying over 12% upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 28.07, and macroeconomic volatility. The stock's fundamentals and institutional support suggest long-term growth potential, but investors should monitor execution on AI investments and spending trends.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →